Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of Efgartigimod Alfa in Healthy Volunteers
NCT03457649Phase 1Completed
- Sponsor
- argenx
- Start
- Sep 2015
- Primary completion
- Nov 2016
- Modality
- Antibody Fragments
01
Overview
Phase 1, randomised, double-blind trial in myasthenia gravis (MG) comparing ARGX-113 with Placebo (2 arms). Primary endpoint: Number of (related) treatment emergent adverse events of single ascending dose at 57 days. Started Sep 2015; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03457649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457649.